CenterWatch
  • Search Clinical Trials
  • Clinical Trial Listings
  • Volunteer
  • Learn About Clinical Trials

Danzhou, China

< 2 Miles
Filters

Type

Distance
Age
0
0
Gender
Trial Phase
Sponsor
  • A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

    Phase

    3

    Span

    367 weeks

    Sponsor

    Mirati Therapeutics Inc.

    Fukushima

    Recruiting

  • A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)

    This study is a randomized, multicenter, double-blind, placebo-controlled phase 2 study (Part 1) followed by an open-label treatment period (Part 2) designed to evaluate the efficacy and safety of pacritinib for the prevention of VEXAS flares after glucocorticoid (GC) taper. The study will enroll patients ≥18 years with inflammatory VEXAS syndrome receiving ongoing GC therapy for ≥4 consecutive weeks, requiring between 15 and 45 mg daily (of prednisone / prednisolone or equivalent) at the time of enrollment (randomization). Patients will be randomized 1:1:1 to receive pacritinib dose A (n=26), pacritinib dose B plus placebo (n=26), or placebo (n=26) for up to 24 weeks during a double-blind treatment period, followed by treatment with pacritinib during an open-label treatment period for up to 48 weeks, and a 30-day post-End of Treatment (EOT) follow-up period. Randomization will be stratified by prescribed GC dose on the day of randomization. All outcomes will be reported by treatment arm, and pair-wise comparison between each pacritinib arm and placebo will be performed in the double-blind treatment period. Patients who complete the double-blind treatment period at End of Week 24 or meet Early Failure criteria at End of Week 12 will transition to an open-label pacritinib treatment period through End of Week 48. In addition, if a study arm closes due to interim futility or safety, all patients currently randomized to that arm will transition to open-label treatment. Study termination is planned approximately 1 year from the first dose of the last patient.

    Phase

    2

    Span

    122 weeks

    Sponsor

    Swedish Orphan Biovitrum

    Fukushima

    Recruiting

  • ONO-4059 Study in Patients With Steroid-resistant Pemphigus

    Phase

    3

    Span

    346 weeks

    Sponsor

    Ono Pharmaceutical Co. Ltd

    Fukushima

    Recruiting

  • A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

    Phase

    3

    Span

    380 weeks

    Sponsor

    GlaxoSmithKline

    Fukushima

    Recruiting

  • A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)

    Phase

    3

    Span

    377 weeks

    Sponsor

    Ipsen

    Fukushima

    Recruiting

  • Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

    Phase

    3

    Span

    248 weeks

    Sponsor

    Merck Sharp & Dohme LLC

    Fukushima

    Recruiting

  • A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    Phase

    3

    Span

    693 weeks

    Sponsor

    Merck Sharp & Dohme LLC

    Fukushima

    Recruiting

  • A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

    Phase

    3

    Span

    341 weeks

    Sponsor

    Bristol-Myers Squibb

    Fukushima

    Recruiting

  • Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures

    Phase

    2

    Span

    222 weeks

    Sponsor

    Ono Pharmaceutical Co. Ltd

    Fukushima

    Recruiting

  • ONO-2017 Study Japanese Patients With Primary Generalized Tonic Clonic Seizures.

    Phase

    3

    Span

    238 weeks

    Sponsor

    Ono Pharmaceutical Co. Ltd

    Fukushima

    Recruiting

1-10 of 41
CenterWatch

5000 Centregreen Way, Suite 200
Cary, NC, 27513, USA

Phone: 703.538.7600
Toll Free: 888.838.5578

  • Disclaimer
  • Privacy Policy
  • Term of Use
  • Do Not Sell My Personal Information